XML 41 R31.htm IDEA: XBRL DOCUMENT

Collaboration and License Agreements - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Nov. 30, 2019	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Collaboration And License Agreements [Line Items]
Research and development expense		$ 13,538,000	$ 6,698,000	$ 25,523,000	$ 12,331,000
Anacor Licensing Agreement
Collaboration And License Agreements [Line Items]
Number of days convenience upon written notice until first regulatory approval.	90 days
Number of days convenience upon written notice thereafter	1 year
Payment of non-refundable upfront payment	$ 2,000,000.0
Research and development expense		$ 0	$ 0	$ 0	$ 0
Aggregate maximum payments upon achievement of development milestones	2,000,000.0
Aggregate maximum payments upon achievement of commercial and sales threshold milestones	$ 125,000,000.0
Royalty percentage	50.00%
Number of years, sales royalty required to be paid	15 years
Brii Biosciences Agreement
Collaboration And License Agreements [Line Items]
Aggregate maximum payments upon achievement of commercial and sales threshold milestones	$ 150,000,000.0
Number of years, sales royalty required to be paid	15 years
Upfront payment received	$ 0
Brii Biosciences Agreement \| Maximum
Collaboration And License Agreements [Line Items]
Aggregate development and regulatory milestones eligible to receive	$ 15,000,000.0